Wearables Get Pain Patients Walking. Why Pain May Persist

A fitness tracker can help someone with chronic back, knee, or widespread musculoskeletal pain walk more. It cannot, on current evidence, promise less pain. A 2025 systematic review of 13 randomized trials found that wearables consistently increased objective physical activity, including steps and moderate-to-vigorous activity, across chronic musculoskeletal conditions. None of the trials produced a statistically significant pain reduction. The review by Eboreime et al. identifies a useful limit: a step count is a behavioral metric, not a pain treatment.

That distinction matters because chronic pain often creates an ugly feedback loop. Pain discourages movement; inactivity can worsen physical function; poor sleep can increase pain sensitivity and make movement harder the next day. A device that records steps may help with one part of that loop. It does not automatically address pacing, sleep, fear of movement, mood, strength, or the reasons a person stopped moving in the first place.

More activity, but no reliable pain benefit

Eboreime and colleagues reviewed randomized controlled trials in adults with chronic low back pain, knee osteoarthritis, fibromyalgia, and rheumatoid arthritis. The wearable interventions differed, and so did their durations: trials ran from 1 to 28 weeks. Across the review, devices increased objectively measured activity. Pain outcomes, measured with instruments such as numerical rating scales, visual analog scales, the Roland Morris Disability Questionnaire, and the Brief Pain Inventory, did not reach statistical significance in any of the 13 trials.

This does not prove that walking cannot reduce pain. It shows that wearable-based activity promotion, as tested in these studies, did not reliably translate its activity gains into a pain outcome. The difference is more than semantic. In knee osteoarthritis, a 2022 systematic review and meta-analysis by Bell et al. found that land-based exercise therapy increases objectively measured physical activity. A separate 2025 systematic review and meta-analysis by Qi et al. found that structured physical activity interventions, including walking and Asian exercise modalities, reduced pain and improved function in middle-aged and older adults with knee osteoarthritis.

Exercise can therefore help in the right program. The weak link may be the gap between "your watch noticed you walked" and a prescription that specifies intensity, progression, recovery, technique, and a response to a bad pain day.

Total steps may be the wrong target

Most wearable programs reward the daily total: 6,000, 8,000, or 10,000 steps. But a 2025 longitudinal study by Hillsdon et al. found that changes in how older adults accumulated steps within the day were more strongly associated with physical function than changes in total daily steps. The study followed 597 community-dwelling adults aged 65 years and older over four assessments across 24 months.

This was an association, not a trial that assigned people to hourly movement prompts or long walking sessions. It cannot establish that spreading steps through the day improves function. Still, it raises an awkward question for step-count programs: why optimize a daily number if the timing and pattern of movement may better track the outcome people actually care about?

For someone whose pain rises after long periods of sitting, brief, tolerable movement breaks may be more realistic than banking all activity in one ambitious walk. For someone who flares after pushing through a high-step day, a daily target can encourage the familiar boom-bust pattern: do too much when symptoms ease, then retreat when they return. The wearable is useful here, but its most valuable feature may be the sedentary alert rather than the badge.

Coaching and adaptive goals add something a device cannot

The strongest practical case for support beyond tracking comes from the ACTION trial. In this 2022 randomized trial, 380 Black veterans with chronic back, hip, or knee pain received a walking-focused intervention with six proactive telephone-coaching sessions over 8 to 14 weeks. The intervention produced a statistically significant advantage in step count and a directional early pain signal at three months. It did not meet its primary six-month disability endpoint: 32.4% of participants in the intervention group versus 24.7% of controls achieved at least a 30% improvement on the Roland Morris Disability Questionnaire (adjusted odds ratio 1.61; 95% CI, 0.94 to 2.77; not statistically significant).

The confidence interval includes no difference, so the six-month result cannot establish a benefit. Yet the pattern is still informative. Early contact may help people start walking, while a short course of coaching may not sustain disability improvement after contact ends. The trial took place at a single VA site and enrolled a population with substantial mental health comorbidity, which limits how confidently its results generalize to every person with musculoskeletal pain.

A wearable-plus-coaching comparison in musculoskeletal pain has not yet isolated coaching's effect on pain as the primary outcome. But a 2025 cardiac rehabilitation randomized trial by Nishio et al. found that weekly online coaching plus a wearable outperformed a wearable alone for physical-activity adherence in people with coronary artery disease. That is not pain evidence, and coronary disease is not osteoarthritis or chronic low back pain. It does support a narrower conclusion: monitoring and sustained behavior change are different jobs.

Goal design also matters. Heapy et al. tested personalized walking integrated into cognitive behavioral therapy for chronic pain. The program calibrated step goals to each participant's actual baseline activity instead of imposing fixed, linear increases. It was safe and feasible. That approach fits pain that fluctuates day to day far better than a one-size-fits-all increase.

Sleep can keep the pain cycle running

Walking is not the only moving part. A 2026 review by Vas-Barna et al. describes a bidirectional relationship among chronic musculoskeletal pain, sleep quality, and physical inactivity. Pain can disrupt sleep; poor sleep can heighten pain sensitivity and lower pain threshold; inactivity can worsen both. The review supports a plausible reason step gains may fail to appear as pain relief: the intervention changes activity while sleep-related sensitization persists.

This remains a framework, not proof that every wearable trial failed because it ignored sleep. The available wearable trials did not appear to systematically measure or control changes in sleep quality, so they cannot separate a walking effect from a sleep-mediated effect. A program that tracks activity should therefore track sleep patterns as context, while treating consumer sleep scores as estimates rather than clinical diagnoses.

Mood may also matter. A 2024 systematic review and meta-analysis by Bizzozero-Peroni et al. found a dose-response association between higher objectively measured daily step counts and lower depression risk in adults. Association does not prove that adding steps prevents depression, nor does it prove a pain mechanism. It does make mood a reasonable outcome to monitor in walking programs, especially where depression and pain coexist.

Why the evidence stays uncertain

Several limitations prevent a clean answer. The 13 wearable trials pooled distinct conditions with different biology and treatment needs. Their interventions lasted anywhere from 1 to 28 weeks, so the evidence cannot identify a minimum duration for pain benefit. They also used different pain instruments, which makes cross-trial comparisons difficult. Eboreime et al. did not report a pooled wearable-specific effect size for physical-activity outcomes, so the size of the activity increase cannot be precisely summarized from that review.

Adherence erodes the apparent effect of any tracker. In a 12-week observational study of working-age adults with hip or knee osteoarthritis, Östlind et al. reported only moderate tracker adherence and a weak correlation between self-reported function and accelerometer-measured activity. A 2026 comparison in taxi drivers with musculoskeletal disorders also found discordance between accelerometry and self-reported activity. That study reinforces a basic measurement problem: self-report and device data do not necessarily tell the same story.

Consumer wearables add another uncertainty. Their accuracy for estimating moderate-to-vigorous activity during impaired gait or limited joint range of motion may vary, and the available evidence does not quantify that error well. More trials alone will not solve the problem if they continue to test static step targets, short follow-up, and pain endpoints disconnected from sleep and pacing.

What to do with a wearable if you have musculoskeletal pain

• Use the device to spot patterns, not to chase a universal number. Look for long sedentary stretches, abrupt activity spikes, and days that predict next-day symptoms.
• Favor distributed movement. Hillsdon et al. found an association between within-day accumulation patterns and function, so regular short bouts are a reasonable experiment when they fit your condition and clinician's advice.
• Set goals from your own baseline. Personalized, adaptive targets make more sense than fixed weekly increases when pain varies.
• Add support when possible. A physiotherapist, structured exercise plan, CBT-informed pacing, or ongoing coaching can supply what a dashboard cannot. The Delaware PEAK trial is testing a related model in knee osteoarthritis: telehealth physical therapy paired with daily step goals.
• Track sleep and symptoms alongside activity. If activity rises while sleep worsens or pain flares, the program needs adjustment rather than more determined badge collecting.

Wearables reliably help many people with chronic musculoskeletal pain move more. Current trials do not show that wearable-guided walking alone reliably delivers clinically meaningful pain relief.

The sensible use of a tracker is modest and specific: make activity visible, pace it to the person, and use the data to guide a broader plan. If pain persists, a higher step total is not a diagnosis, a treatment plan, or a reason to ignore a flare.